# A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies

> **NCT00761696** · PHASE1 · COMPLETED · sponsor: **Infinity Pharmaceuticals, Inc.** · enrollment: 94 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** IPI-926

## Key facts

- **NCT ID:** NCT00761696
- **Lead sponsor:** Infinity Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2012-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00761696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00761696, "A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00761696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*